A Phase 1, Open Label, Dose Escalation Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of Combined Oral C- MET/ALK Inhibitor (PF- 02341066) And PAN-HER Inhibitor (PF- 00299804) In Patients With Advanced Non-Small Cell Lung Cancer

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Overall safety profile of combined PF 02341066 plus PF 00299804 including adverse events (AE), as defined and graded by the National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE], and first cycle Dose Limiting Toxicity.

Outcome Time Frame:

18 months

Safety Issue:

Yes

Principal Investigator

Pfizer CT.gov Call Center

Investigator Role:

Study Director

Investigator Affiliation:

Pfizer

Authority:

United States: Food and Drug Administration

Study ID:

A8081006

NCT ID:

NCT01121575

Start Date:

August 2010

Completion Date:

August 2013

Related Keywords:

• Non Small Cell Lung Cancer
• Phase 1 acquired resistance to erlotinib or gefitinib cMET inhibitor EGFR inhibitor panHER inhibitor combination trial Crizotinib
• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms